FDG-PET 在检测髓系恶性肿瘤患者的粒细胞肉瘤方面是有效的。

FDG-PET is effective in the detection of granulocytic sarcoma in patients with myeloid malignancy.

机构信息

Department of Hematology and Oncology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

出版信息

Leuk Res. 2010 Sep;34(9):1239-41. doi: 10.1016/j.leukres.2010.04.017. Epub 2010 May 20.

DOI:10.1016/j.leukres.2010.04.017

PMID:20493526

Abstract

Granulocytic sarcomas (GSs) are extramedullary tumors that consist of myeloid cells in patients with myeloid malignancies. The role for (18)F-fluorodeoxyglucose-positron-emission tomography (FDG-PET) to detect GSs has been unclear. We retrospectively evaluated seven patients with pathologically proven GSs. Compared with other diagnostic tools, FDG-PET was more effective or at least equivalent in the detection of GSs in six patients, but was less effective in one patient. Maximum standardized uptake value (SUVmax) for the lesions widely varied from 2.6 to 9.7. When our findings and previous reports taken together, FDG-PET is an effective tool to search for GSs, however, other diagnostic tools including computed tomography (CT) are still necessary to detect morphological abnormalities.

摘要

粒细胞肉瘤（GSs）是由髓系恶性肿瘤患者的髓系细胞组成的髓外肿瘤。（18）F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）在检测 GSs 中的作用尚不清楚。我们回顾性评估了 7 名经病理证实的 GSs 患者。与其他诊断工具相比，FDG-PET 在 6 名患者中检测 GSs 的效果更有效或至少等效，但在 1 名患者中效果较差。病变的最大标准化摄取值（SUVmax）从 2.6 到 9.7 不等。当我们的发现与之前的报告结合起来时，FDG-PET 是一种有效的寻找 GSs 的工具，然而，包括计算机断层扫描（CT）在内的其他诊断工具仍然是检测形态异常所必需的。